GLP-1 receptor agonists are introduced through a slow titration protocol — starting at a sub-therapeutic dose and increasing every 4 weeks — because the most common side effects (nausea, vomiting, constipation, diarrhea) are dose-dependent and most severe during dose transitions. The titration protocol exists to allow the GI tract to adapt. Understanding the schedule, what to expect at each step, and when to pause or slow the escalation significantly improves tolerability and reduces dropout.
Approximately 5–10% of trial participants discontinued due to GI side effects in the STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) pivotal trials. In real-world practice, dropout rates are higher, partly because patients aren't adequately prepared for what each dose transition involves. This guide covers both FDA-approved brand-name titration schedules and evidence-based strategies for managing side effects at each step.
| Weeks | Dose | Injection | Notes |
|---|---|---|---|
| Weeks 1–4 | 0.25mg/week | Subcutaneous, once weekly | Starting dose; not therapeutic for blood sugar — tolerance building only |
| Weeks 5–8 | 0.5mg/week | Subcutaneous, once weekly | First therapeutic dose; nausea most common here |
| Weeks 9–12 | 1mg/week (if needed) | Subcutaneous, once weekly | Standard maintenance for many T2D patients |
| Week 13+ | 2mg/week (if needed) | Subcutaneous, once weekly | Maximum approved dose for T2D; added in 2022 |
| Weeks | Dose | Notes |
|---|---|---|
| Weeks 1–4 | 0.25mg/week | Starting dose; tolerance induction |
| Weeks 5–8 | 0.5mg/week | Appetite suppression begins; nausea peaks during transition |
| Weeks 9–12 | 1mg/week | Significant appetite reduction at this dose for most patients |
| Weeks 13–16 | 1.7mg/week | Near-maximum dose; another tolerance challenge period |
| Week 17+ | 2.4mg/week | Target maintenance dose used in STEP-1 trial (−14.9% body weight at 68 weeks) |
Extended titration option: If nausea is intolerable during a dose increase, staying at the previous dose for an additional 4 weeks before escalating is explicitly permitted by prescribing guidelines. There is no clinical penalty for a slower schedule. Many patients benefit from taking 6–8 weeks (vs. 4) at each step.
Tirzepatide (GIP + GLP-1 dual agonist) has a similar titration structure but reaches a higher maximum dose. It consistently outperforms semaglutide in head-to-head comparisons (SURMOUNT-5: −20.2% vs. −13.7% body weight).
| Weeks | Dose | Notes |
|---|---|---|
| Weeks 1–4 | 2.5mg/week | Starting dose; GI side effects usually mild |
| Weeks 5–8 | 5mg/week | First significant appetite suppression; nausea peak |
| Weeks 9–12 | 7.5mg/week | Many T2D patients maintained here (Mounjaro) |
| Weeks 13–16 | 10mg/week | Strong appetite suppression; nausea usually subsided by this point |
| Weeks 17–20 | 12.5mg/week | Near-maximum; used in obesity trials (Zepbound) |
| Week 21+ | 15mg/week | Maximum approved dose; SURMOUNT-1 primary endpoint dose |
What to expect: Minimal side effects for most patients. Mild nausea in ~20% of patients, usually in the 24–48 hours following injection. No significant weight loss at this dose — this is purely tolerance induction.
Injection technique: Inject on the same day each week. Abdomen, outer thigh, and outer upper arm are all approved sites — rotate locations. Inject at room temperature (remove pen from fridge 30 minutes before use) to reduce injection site discomfort.
What to expect: This is when most people experience peak nausea. It typically occurs 6–24 hours post-injection and lasts 1–3 days, then subsides. Reduced appetite is now noticeable — smaller portions feel satisfying. Some patients experience constipation starting here.
What to expect: GI tolerance usually improves significantly. Most patients find that nausea at mid-titration doses is much less severe than at the first therapeutic dose — the GI tract has adapted. Appetite suppression deepens. Constipation is common (see constipation management below). Weight loss is now visible.
Constipation management: Actively increase dietary fiber (25–35g/day target), hydration (2.5L+/day), and physical activity. If insufficient, add psyllium husk (5–10g/day with water) or osmotic laxative (PEG/MiraLax). Do not ignore constipation — it worsens as doses increase and is a common reason for discontinuation.
What to expect: Most patients who reach the maximum dose have developed significant tolerance to GI side effects. Appetite suppression is at its greatest. Some patients plateau weight loss at this point — this is normal and expected, not a sign the medication stopped working.
Not everyone needs the maximum dose: If you have achieved your weight loss goal or are satisfied with your response at a lower dose, staying at that dose is medically appropriate. The maximum dose is a ceiling, not a requirement.